Comprehensive genomic profiling · curated MDI catalog

Comprehensive genomic profiling cancer tests

Comprehensive genomic profiling examines many cancer-related genomic alterations in one assay. A finding does not automatically determine treatment; interpretation depends on cancer type, evidence and clinical context.

13 curated profiles currently match this page. MDI lists them alphabetically and does not rank tests by isolated performance numbers, evidence counts, price or popularity.

  • Altera — Tumor comprehensive genomic profiling using whole-exome and whole-transcriptome sequencing.
  • FoundationOne CDx — Tissue-based comprehensive genomic profiling and indication-specific companion diagnostic for solid tumors.
  • FoundationOne Heme — DNA/RNA comprehensive genomic profiling LDT for hematologic neoplasms and other source-defined indications.
  • FoundationOne Liquid CDx — Blood-based 324-gene comprehensive genomic profiling and companion-diagnostic test for advanced solid tumors. Regulatory claims are PMA-, supplement-, biomarker-, therapy- and indication-scoped.
  • Guardant360 Liquid CDx — Plasma cfDNA comprehensive genomic profiling and indication-specific companion diagnostic.
  • MSK-ACCESS — Institutional ultra-deep cfDNA sequencing assay for noninvasive genomic profiling and disease monitoring; current panel covers 146 genes.
  • NEO PanTracer LBx — 514-gene ctDNA liquid-biopsy comprehensive genomic profiling assay for advanced pan-solid tumors, including MSI-H and bTMB.
  • NEO PanTracer Tissue — 517-gene DNA/RNA tissue comprehensive genomic profiling for solid tumors.
  • Northstar Select — 102-gene plasma ctDNA comprehensive genomic profiling assay for therapy selection in advanced solid tumors.
  • OncoExTra — Whole-exome and whole-transcriptome tumor profiling with matched-normal subtraction for advanced solid tumors.
  • Tempus xF+ — 523-gene plasma liquid-biopsy comprehensive genomic profiling assay for therapy selection and molecular profiling in advanced cancer.
  • Tempus xT CDx — 648-gene tissue comprehensive genomic profiling companion diagnostic.
  • TruSight Oncology Comprehensive — DNA/RNA comprehensive genomic profiling assay for solid tumors with indication-specific companion-diagnostic claims.

How to interpret these records

Clinical purpose comes first. Historical evidence remains attached to the assay version that was actually studied. Evidence counts describe curation coverage, not test quality. Commercial availability is separate from authorization, reimbursement, eligibility and appropriate use.

Find all tests · Understand the evidence · Methodology & provenance